> Shire says that the FDA has told the company that it hasn't been able to make a decision on its concerns that copycat versions of Adderall XR are too easy to produce. Shire wants the agency to require more rigorous bioequivalence testing. Report
> Iceland's Actavis has raised its bid for Pliva by 11 percent. Report
> Omrix Biopharmaceuticals has priced its IPO at $10 a share. Report
> NovaDel has raised $12 million from a stock sale to fund new clinical development work. Release
> Akorn and India's Natco have inked a deal to commercial two injectable therapies. Release
> An updated safety review by Nymox of NX-1207 for benign prostatic hyperplasia has revealed no serious side effects. Report
> GTx is launching a Phase IIIb trial of Acapodene in men undergoing androgen deprivation therapy for prostate cancer. Report
> The FDA has yet to complete a review of Advancis' marketing approval request for additional Keflex products. Keflex is a popular antibiotic. Release
And Finally… Researchers have found a genetic link for the hard-to-diagnose chronic fatigue syndrome. Article